Genetic Analysis AS
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more
Genetic Analysis AS (GEAN) - Net Assets
Latest net assets as of September 2025: Nkr29.54 Million NOK
Based on the latest financial reports, Genetic Analysis AS (GEAN) has net assets worth Nkr29.54 Million NOK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr43.84 Million) and total liabilities (Nkr14.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr29.54 Million |
| % of Total Assets | 67.37% |
| Annual Growth Rate | -16.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 37.74 |
Genetic Analysis AS - Net Assets Trend (2020–2024)
This chart illustrates how Genetic Analysis AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genetic Analysis AS (2020–2024)
The table below shows the annual net assets of Genetic Analysis AS from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr22.49 Million | -29.70% |
| 2023-12-31 | Nkr32.00 Million | -27.51% |
| 2022-12-31 | Nkr44.14 Million | -38.77% |
| 2021-12-31 | Nkr72.09 Million | +54.62% |
| 2020-12-31 | Nkr46.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genetic Analysis AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1476900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr37.26 Million | 165.66% |
| Total Equity | Nkr22.49 Million | 100.00% |
Genetic Analysis AS Competitors by Market Cap
The table below lists competitors of Genetic Analysis AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Azincourt Uranium Inc
OTCQB:AZURF
|
$1.89 Million |
|
WD-40 CO (WD1.SG)
STU:WD1
|
$1.90 Million |
|
Shrenik Limited
NSE:SHRENIK
|
$1.90 Million |
|
JE Cleantech Holdings Ltd
NASDAQ:JCSE
|
$1.90 Million |
|
Fiddlehead Resources Corp.
V:FHR
|
$1.89 Million |
|
Hansol Chemical Co. Ltd.
KQ:014680
|
$1.89 Million |
|
Hall of Fame Resort Entertainment Co
NASDAQ:HOFV
|
$1.89 Million |
|
CAPELLI NOM. EO 684
F:CP0
|
$1.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genetic Analysis AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,998,000 to 22,493,000, a change of -9,505,000 (-29.7%).
- Net loss of 14,769,000 reduced equity.
- New share issuances of 5,420,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-14.77 Million | -65.66% |
| Share Issuances | Nkr5.42 Million | +24.1% |
| Other Changes | Nkr-156.00K | -0.69% |
| Total Change | Nkr- | -29.70% |
Book Value vs Market Value Analysis
This analysis compares Genetic Analysis AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.34x to 1.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Nkr1.86 | Nkr0.64 | x |
| 2021-12-31 | Nkr2.87 | Nkr0.64 | x |
| 2022-12-31 | Nkr1.76 | Nkr0.64 | x |
| 2023-12-31 | Nkr0.80 | Nkr0.64 | x |
| 2024-12-31 | Nkr0.44 | Nkr0.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genetic Analysis AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -65.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -92.97%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.88x
- Recent ROE (-65.66%) is below the historical average (-58.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -47.48% | -382.99% | 0.10x | 1.19x | Nkr-26.80 Million |
| 2021 | -40.23% | -426.57% | 0.08x | 1.16x | Nkr-36.21 Million |
| 2022 | -64.05% | -253.28% | 0.17x | 1.46x | Nkr-32.69 Million |
| 2023 | -74.44% | -168.36% | 0.26x | 1.67x | Nkr-27.02 Million |
| 2024 | -65.66% | -92.97% | 0.37x | 1.88x | Nkr-17.02 Million |
Industry Comparison
This section compares Genetic Analysis AS's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $129,852,000
- Average return on equity (ROE) among peers: -3.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genetic Analysis AS (GEAN) | Nkr29.54 Million | -47.48% | 0.48x | $1.89 Million |
| AroCell AB (AROC) | $222.69 Million | -26.48% | 0.06x | $6.76 Million |
| Devyser Diagnostics AB (DVYSR) | $37.01 Million | 18.94% | 0.99x | $80.66 Million |